Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.20%19 ROA % is 2.75% as of Dec. 2025, which is 17% above its 10-year median of 2.35. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 52.33% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Pet Pharm Biotech Co's annualizedNet Income for the quarter that ended in Dec. 2025 was NT$33.8 Mil.
Pet Pharm Biotech Co's average Total Assets over the quarter that ended in Dec. 2025 was NT$1,225.8 Mil. Therefore, Pet Pharm Biotech Co's annualized ROA % for the quarter that ended in Dec. 2025 was 2.75%.
The historical rank and industry rank for Pet Pharm Biotech Co's ROA % or its related term are showing as below:
ROCO:7762'
s ROA % Range Over the Past 10 Years
Min: -1.99 Med: 2.35 Max: 2.69
Current: 2.33
During the past 4 years, Pet Pharm Biotech Co's highest ROA % was 2.69%. The lowest was -1.99%. And the median was 2.35%.
ROCO:7762's ROA % is ranked worse than 52.33% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.78
vs ROCO:7762: 2.33
Pet Pharm Biotech Co (ROCO:7762) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's ROA % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Pet Pharm Biotech Co (ROCO:7762) has a ROA % of 2.75% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pet Pharm Biotech Co and its competitors. This is 17% above median its historical median of 2.35. According to the industry distribution chart, Pet Pharm Biotech Co ranks #527 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Pet Pharm Biotech Co's ROA % too high?
Pet Pharm Biotech Co's current ROA % of 2.75% is 17% above median its 10-year median of 2.35. The Drug Manufacturers industry median ROA % is 2.78. Pet Pharm Biotech Co's value of 2.75% is 1.1% below this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #527 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's ROA % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #527 out of 1007 companies for ROA %. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median ROA % is 2.78. Pet Pharm Biotech Co's value of 2.75% is 1.1% below this benchmark. While the company's 10-year median is 2.35 vs. the industry median of 2.78, Pet Pharm Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.78, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current ROA % of 2.75% is 1.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current ROA % is 2.75%, which is 17% above median its own 10-year median of 2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current ROA % of 2.75%. The current ROA % is 2.75%, which is 17% above median its 10-year median of 2.35 and 1.1% below the Drug Manufacturers industry median of 2.78. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current ROA % is 2.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
